Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Playtex Q1 results

This article was originally published in The Rose Sheet

Executive Summary

Banana Boat sun care sales grew 6.5% to $53.8 mil. in first quarter due to effective pre-season sell-in and positive impact of the firm's ongoing initiative to improve sun care returns, Playtex reports in Q1 1sales and earnings release. Company launched Banana Boat Suntanicals SPF 8 and SPF 16 lotions and a three-SKU line of Baby Magic Sun Block by Banana Boat this year (2"The Rose Sheet" July 29, 2002, p. 5). Infant care sales fell 10.3% to $58.8 mil. compared to the year-ago period due in part to lower sales of baby wipes business, CEO Michael Gallagher tells analysts April 29. Consolidated sales were off 8.1% to $180.9 mil., while net earnings dropped 29.2% to $11.4 mil. compared with earnings of $16.1 mil. a year ago on an as-reported basis...

You may also be interested in...



Playtex Suncare Inventory Management Aims To Stem Tide Of Returns

Playtex Products will use historical consumption patterns for individual retailers in an attempt to better align Banana Boat suncare product shipments with consumer demand and reduce product returns

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel